A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma

por Care, Matthew A., Barrans, Sharon, Worrillow, Lisa, Jack, Andrew, Westhead, David R., Tooze, Reuben M.
Publicado 2013

Fluorescent polymerase chain reaction of a panel of CA repeats on chromosome 6 in the indolent phase of follicular centre cell lymphoma.

por Randerson, J., Cawkwell, L., Jack, A., Lewis, F., Johnson, P., Evans, P., Barrans, S., Morgan, G. J.
Publicado 1996

Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas

por Sha, Chulin, Barrans, Sharon, Care, Matthew A., Cunningham, David, Tooze, Reuben M., Jack, Andrew, Westhead, David R.
Publicado 2015

A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore s...

por Maishman, Tom, Stanton, Louise, Davies, Andy, Barrans, Sharon, Worrillow, Lisa, Mamot, Christoph, Care, Matt, Immins, Tikki, Hamid, Debbie, McMillan, Andrew, Fields, Paul, Jack, Andrew, Johnson, Peter
Publicado 2013

SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity

por Care, Matthew A., Cocco, Mario, Laye, Jon P., Barnes, Nicholas, Huang, Yuanxue, Wang, Ming, Barrans, Sharon, Du, Ming, Jack, Andrew, Westhead, David R., Doody, Gina M., Tooze, Reuben M.
Publicado 2014

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial()

por McMillan, A.K., Phillips, E.H., Kirkwood, A.A., Barrans, S., Burton, C., Rule, S., Patmore, R., Pettengell, R., Ardeshna, K.M., Lawrie, A., Montoto, S., Paneesha, S., Clifton-Hadley, L., Linch, D.C.
Publicado 2020

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for...

por Davies, Andrew, Barrans, Sharon, Burton, Cathy, Mercer, Katy, Caddy, Joshua, Chinnery, Fay, Day, Laura, Fernando, Diana, Ardeshna, Kirit, Collins, Graham, Radford, John, Rule, Simon, McMillan, Andrew, Johnson, Peter, Griffiths, Gareth
Publicado 2020

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

por Phillips, Elizabeth H., Burton, Catherine, Kirkwood, Amy A., Barrans, Sharon, Lawrie, Anthony, Rule, Simon, Patmore, Russell, Pettengell, Ruth, Ardeshna, Kirit M., Montoto, Silvia, Paneesha, Shankara, Clifton‐Hadley, Laura, Linch, David C., McMillan, Andrew K.
Publicado 2020

Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL

por Davies, John R., Hilton, Laura K., Jiang, Aixiang, Barrans, Sharon, Burton, Catherine, Johnson, Peter W. M., Davies, Andrew J., Du, Ming-Qing, Tooze, Reuben, Cucco, Francesco, Care, Matthew A., Morin, Ryan D., Steidl, Christian, Sha, Chulin, Westhead, David R., Scott, David W.
Publicado 2023

Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network

por Crouch, Simon, Painter, Daniel, Barrans, Sharon L., Roman, Eve, Beer, Philip A., Cooke, Susanna L., Glover, Paul, Van Hoppe, Suzan J.L., Webster, Nichola, Lacy, Stuart E., Ruiz, Camilo, Campbell, Peter J., Hodson, Daniel J., Patmore, Russell, Burton, Cathy, Smith, Alexandra, Tooze, Reuben M.
Publicado 2022

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

por Sha, Chulin, Barrans, Sharon, Cucco, Francesco, Bentley, Michael A., Care, Matthew A., Cummin, Thomas, Kennedy, Hannah, Thompson, Joe S., Uddin, Rahman, Worrillow, Lisa, Chalkley, Rebecca, van Hoppe, Moniek, Ahmed, Sophia, Maishman, Tom, Caddy, Josh, Schuh, Anna, Mamot, Christoph, Burton, Catherine, Tooze, Reuben, Davies, Andrew, Du, Ming-Qing, Johnson, Peter W.M., Westhead, David R.
Publicado 2019

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up

por Davies, Andrew J., Barrans, Sharon, Stanton, Louise, Caddy, Josh, Wilding, Sam, Saunders, Geoff, Mamot, Christoph, Novak, Urban, McMillan, Andrew, Fields, Paul, Collins, Graham P., Stephens, Richard, Cucco, Francesco, Sha, Chulin, van Hoppe, Moniek, Tooze, Reuben, Davies, John R., Griffiths, Gareth, Schuh, Anna, Burton, Catherine, Westhead, David R., Du, Ming-Qing, Johnson, Peter W.M.
Publicado 2023

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

por Cucco, Francesco, Barrans, Sharon, Sha, Chulin, Clipson, Alexandra, Crouch, Simon, Dobson, Rachel, Chen, Zi, Thompson, Joe Sneath, Care, Matthew A., Cummin, Thomas, Caddy, Josh, Liu, Hongxiang, Robinson, Anne, Schuh, Anna, Fitzgibbon, Jude, Painter, Daniel, Smith, Alexandra, Roman, Eve, Tooze, Reuben, Burton, Catherine, Davies, Andrew J., Westhead, David R., Johnson, Peter W. M., Du, Ming-Qing
Publicado 2019

The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit

por Clipson, Alexandra, Barrans, Sharon, Zeng, Naiyan, Crouch, Simon, Grigoropoulos, Nicholas F, Liu, Hongxiang, Kocialkowski, Sylvia, Wang, Ming, Huang, Yuanxue, Worrillow, Lisa, Goodlad, John, Buxton, Jenny, Neat, Michael, Fields, Paul, Wilkins, Bridget, Grant, John W, Wright, Penny, EI‐Daly, Hesham, Follows, George A, Roman, Eve, Watkins, A James, Johnson, Peter W M, Jack, Andrew, Du, Ming‐Qing
Publicado 2015

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

por Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M
Publicado 2019

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

por Kizhakeyil, Atish, Zaini, Nurmahirah Binte Mohammed, Poh, Zhi Sheng, Wong, Brandon Han Siang, Loh, Xinpeng, Ng, Aik Seng, Low, Zun Siong, Prasannan, Praseetha, Gong, Chun, Tan, Michelle Guet Khim, Nagarajan, Chandramouli, Huang, Dachuan, Lu, Pang Wan, Lim, Jing Quan, Barrans, Sharon, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Follows, George, Hodson, Daniel J., Du, Ming Qing, Goh, Yeow Tee, Tan, Suat Hoon, Grigoropoulos, Nicholas Francis, Verma, Navin Kumar
Publicado 2021

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

por Bewicke-Copley, Findlay, Korfi, Koorosh, Araf, Shamzah, Hodkinson, Brendan, Kumar, Emil, Cummin, Thomas, Ashton-Key, Margaret, Barrans, Sharon, van Hoppe, Suzan, Burton, Cathy, Elshiekh, Mohamed, Rule, Simon, Crosbie, Nicola, Clear, Andrew, Calaminici, Maria, Runge, Hendrik, Hills, Robert K., Scott, David W., Rimsza, Lisa M., Menon, Geetha, Sha, Chulin, Davies, John R., Nagano, Ai, Davies, Andrew, Painter, Daniel, Smith, Alexandra, Gribben, John, Naresh, Kikkeri N., Westhead, David R., Okosun, Jessica, Steele, Andrew, Hodson, Daniel J., Balasubramanian, Sriram, Johnson, Peter, Wang, Jun, Fitzgibbon, Jude
Publicado 2022